March 4, 2026 expert reaction to cohort study on GLP-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes . A cohort study published in T ...

By Michael Erman and Puyaan Singh March 5 (Reuters) - A senior FDA official called UniQure's experimental treatment for ...

Treatment-naïve BRVO eyes showed logMAR BCVA improvement (0.64 to 0.41) alongside CRT reduction (527 µm to 285 µm) over short-term follow-up with SB15. Central RVO eyes improved from logMAR 1.29 to 0.

Inflation Reduction Act tied to stronger medication adherence among Medicare enrollees after 2024 drug cost provisions took effect.

Retention has always been a central concern in long-term studies, but obesity trials present a particular challenge. For those assigned to receive the drug candidate in question, the effects are ...

Greetings, and welcome to the HeartBeam Fourth Quarter 2025 Financial Results Conference Call. [Operator Instructions]. As a reminder, today's conference is being recorded. Before we begin the formal ...

In a strikingly blunt briefing, a senior FDA official accused uniQure of pushing “distorted” data to mask a “failed” therapy ...

China’s research transformation offers a fascinating and, in some respects, outlying comparator for the rest of the world (“The ascent of China’s universities”, The Big Read, February 27). Yet those ...

Apogee Therapeutics (NASDAQ:APGE) outlined a series of near- and mid-term clinical milestones at TD Cowen’s 46th Annual ...

This review in Nutrients evaluates the scientific evidence, clinical effectiveness, and safety of major dietary strategies for irritable bowel syndrome, including traditional advice, low-FODMAP, ...

Novo Nordisk plunges after CagriSema REDEFINE 4 misses vs. tirzepatide. Click here to read my most recent analysis of NVO stock.

The FDA is slated to make a decision on the flu shot on Aug. 5, which will allow Moderna to make the vaccine available for the upcoming influenza season.